Do Carbohydrates Feed Cancer?

Cancer cells do consume more glucose than most normal cells, and that biological fact is the seed of a persistent idea: that eating carbohydrates somehow fuels tumor growth. The reality is far more complicated. Your body maintains blood sugar within a narrow range regardless of what you eat, and tumors are remarkably good at extracting the glucose they need even when circulating levels are low. The relationship between carbohydrates and cancer is real, but it runs through hormones, metabolic health, and immune function rather than through a simple pipeline from your plate to a tumor.

Why Cancer Cells Love Glucose

In the 1920s, a German physiologist named Otto Warburg noticed something odd: cancer cells gobble up glucose and convert it to lactate at an unusually high rate, even when there is plenty of oxygen available for the more efficient energy pathway that normal cells prefer. This behavior, now called the Warburg effect, has been confirmed across a wide range of tumor types and remains one of the most consistent features of cancer metabolism.¹ Normal differentiated cells generate most of their energy through a process that extracts far more energy per molecule of glucose, but most cancer cells instead lean heavily on this less efficient, faster route.²

To pull this off, cancer cells ramp up their glucose transporters, especially a protein called GLUT1, which sits on the cell surface and ferries glucose inside. Many cancers dramatically increase GLUT1 levels to ensure a steady flow of sugar into the cell’s metabolic machinery.³ This upregulation of glucose transporters has been documented across numerous cancer types.⁴ The reason tumors do this is not entirely about energy. Rapidly dividing cells need raw materials to build new DNA, proteins, and membranes, and the fast-burn glucose pathway generates useful chemical intermediates for those building projects.

Warburg originally believed cancer cells were stuck with this strategy because their mitochondria were broken. That turns out to be wrong. Most tumors have perfectly functional mitochondria. The metabolic shift is instead a deliberate reprogramming driven by an interplay of gene mutations, growth signals, and the tumor’s local environment.⁵ This distinction matters: cancer cells are not helplessly dependent on glucose. They are choosing to prioritize it while retaining the ability to use other fuels when they need to.

Why “Starving” a Tumor of Sugar Does Not Work the Way You Might Think

The intuitive leap is straightforward: if tumors use a lot of glucose, then eating fewer carbs should deprive them. The problem is that your body has powerful systems dedicated to keeping blood sugar within a tight range, roughly 70 to 100 mg/dL when fasting. If you stop eating carbs entirely, your liver starts making glucose from protein and fat through a process called gluconeogenesis. Your brain, your red blood cells, and your muscles all require glucose, so your body will manufacture it no matter what you eat. A tumor embedded in your tissue has access to whatever glucose is circulating in the blood, and that glucose is always there.

This means that cutting carbs from your diet does not create a glucose desert in the neighborhood of a tumor. It lowers blood sugar modestly and briefly, but cancers with upregulated glucose transporters are extremely efficient scavengers. They can pull glucose from the bloodstream at concentrations that would barely register for a normal cell.

What Actually Matters Is Metabolic Health

If simply eating carbs is not the issue, what is? The evidence points much more strongly to chronic metabolic problems, particularly insulin resistance, sustained high blood sugar, and the hormonal changes that accompany them. Persistently elevated blood glucose, or hyperglycemia, provides tumor cells with an excessive supply of their preferred fuel and also triggers biological changes that make cancer more aggressive, including resistance to cell death and reduced effectiveness of chemotherapy.⁶ Epidemiological research has linked lifestyle patterns that keep blood sugar chronically high to increased cancer risk, faster tumor progression, and higher mortality.⁷

Insulin resistance compounds the problem. When cells stop responding well to insulin, the pancreas pumps out more of it to compensate. High circulating insulin stimulates growth-promoting pathways, including insulin-like growth factor 1 receptor (IGF-1R), which can encourage tumor cells to proliferate and resist treatment.⁸ A growing body of evidence links insulin resistance itself to the development of various cancers.⁹ Broader metabolic dysfunction, including obesity and metabolic syndrome, has been tied to increased risk of and death from colorectal, pancreatic, postmenopausal breast, and bladder cancers.¹⁰

The upshot is that the type and pattern of carbohydrate intake, and the metabolic condition of the person eating them, matter far more than the raw quantity. A person with well-controlled blood sugar who eats a bowl of brown rice is in a very different metabolic situation from someone with uncontrolled diabetes drinking a large soda.

Not All Carbohydrates Are Created Equal

The idea that “carbs feed cancer” treats all carbohydrates as interchangeable, which they are not. A slice of white bread, a handful of lentils, and a glass of fruit juice all contain carbohydrates, but they behave very differently once digested. Rapidly digested carbohydrates that spike blood sugar (high glycemic index foods) appear to carry more risk than slowly digested ones.

In a large Italian cohort study, people who ate the most high-glycemic-index foods had roughly 35 to 45 percent higher odds of colorectal cancer compared to those who ate the least. Meanwhile, people whose carbohydrate intake came primarily from low-glycemic-index sources actually had a lower risk.¹¹ An earlier case-control study found a similar pattern, with higher glycemic load linked to about 80 percent higher odds of colorectal cancer in the top versus bottom group, an association amplified by being overweight or eating little fiber.¹²

Fiber, a carbohydrate that humans cannot digest, tells a different story entirely. When gut bacteria ferment dietary fiber, they produce short-chain fatty acids like butyrate, which have been shown to play protective roles in colorectal cancer development and progression.¹³ So one type of carbohydrate may modestly raise cancer risk while another type of carbohydrate helps protect against it. Lumping them together under a single “carbs feed cancer” label obscures this critical distinction.

Sugary Drinks and the Clearest Dietary Signal

If any carbohydrate source deserves scrutiny, it is sugar-sweetened beverages. These deliver large doses of rapidly absorbed sugar without fiber, fat, or protein to slow the glucose spike. A large French cohort found that for every additional 100 mL per day of sugary drink consumption (a small glass), overall cancer risk rose by about 18 percent and breast cancer risk by about 22 percent.¹⁴ A meta-analysis of observational studies found that people with the highest sugar-sweetened beverage intake had about 12 percent higher overall cancer risk than those with the lowest intake, along with modestly higher cancer mortality.¹⁵ Another systematic review linked sugar-sweetened beverages to higher breast and prostate cancer risk specifically.¹⁶

These are observational findings, and people who drink a lot of soda also tend to have other risk factors. But the consistency across studies, and the biological plausibility through insulin and blood-sugar pathways, makes the association difficult to dismiss. It is worth noting, though, that a systematic review and meta-analysis looking at overall dietary carbohydrate quantity found no clear link between the highest versus lowest carbohydrate intake and cancer mortality.¹⁷ The pattern is consistent: the quality of the carbohydrates you eat seems to matter; the total amount, less so.

Fructose Has Its Own Story

Glucose gets most of the attention in cancer metabolism, but fructose, the sugar abundant in fruit juice, high-fructose corn syrup, and table sugar, is emerging as a concern in its own right. Cancer cells can use fructose through pathways that are distinct from glucose metabolism, and in some cases these pathways may be particularly useful for tumor growth. Fructose enters the metabolic pipeline downstream of glucose, bypassing two key rate-limiting steps, which can accelerate the flow of carbon into cancer-promoting pathways.¹⁸

In pancreatic cancer cells, researchers found that fructose and glucose are handled quite differently. Fructose was preferentially routed into a pathway that generates the building blocks for DNA synthesis.¹⁹ More recent work has shown that fructose metabolism supports tumor growth, spread, and even resistance to therapy, especially when glucose is scarce.²⁰ This does not mean that eating an apple is dangerous. Whole fruit delivers fructose slowly alongside fiber. But it adds another layer to the argument against large quantities of added sugars and sweetened beverages, where fructose arrives in concentrated, rapidly absorbed form.

PET Scans Prove the Biology but Not the Diet Claim

One reason the “carbs feed cancer” idea has such staying power is PET scanning. In a PET scan, doctors inject a radioactive glucose analog called FDG. Because cancer cells consume more glucose than surrounding tissue, the tracer pools in tumors, lighting them up on the scan.²¹ The technique relies directly on the increased glucose consumption of cancer cells.²²

People sometimes see PET scans as proof that sugar feeds cancer: look, the tumor is pulling in all that glucose! But PET scans work precisely because the glucose is already circulating in your blood at normal physiological levels. The tumor is not lighting up because you ate a muffin that morning. It lights up because its glucose transporters are cranked up high enough to grab glucose faster than surrounding tissue. The scan demonstrates a feature of cancer biology; it does not demonstrate that dietary carbohydrate restriction would dim the signal.

Tumors Can Switch Fuels

Even if you could meaningfully reduce glucose delivery to a tumor, cancer cells are metabolically flexible. Research has shown that tumors can use alternative fuels including glutamine, lactate, and fatty acids. Highly glycolytic tumor cells produce large amounts of lactate, which can then be shuttled to neighboring cancer cells or surrounding tissue cells and burned as fuel, creating a kind of metabolic relay within the tumor.²³ Some melanoma cells, when deprived of glutamine, showed partial survival even at low glucose concentrations, with certain antioxidants and metabolic intermediates partially compensating for the missing nutrients.²⁴

This metabolic plasticity is one of the biggest challenges in targeting cancer metabolism. Tumors are not simple machines that shut down when you unplug one power source. They adapt, rewire, and find workarounds. This is why the idea of starving cancer through diet alone has not panned out as a standalone treatment, even though manipulating tumor metabolism is an active area of drug research.

Ketogenic Diets and Fasting as Cancer Therapies

The most organized attempt to exploit cancer’s glucose dependence is the ketogenic diet, a very-low-carbohydrate, high-fat eating pattern that forces the body to burn fat and produce ketone bodies for fuel. The theoretical logic is that cancer cells, being more dependent on glucose, would struggle under these conditions while normal cells adapt. A review of the evidence concluded that ketogenic diets may be safely used as an add-on to conventional radiation and chemotherapy and that limiting glucose while increasing ketone availability could selectively stress cancer cells.²⁵

Fasting and fasting-mimicking diets follow a related logic, creating temporary periods of low glucose and low insulin. Animal studies strongly support this approach, and a small number of human trials have shown encouraging results for cancer patients.²⁶ In a randomized trial of breast cancer patients receiving chemotherapy, those assigned to a fasting-mimicking diet alongside treatment had better tumor responses, with more patients in the fasting group achieving substantial or complete tumor cell loss in their surgical specimens.²⁷

These results are genuinely interesting, but they come with important caveats. Ketogenic diets and fasting were studied as additions to standard treatment, not replacements. The human evidence is still thin, based on small studies. And for patients who are already losing weight involuntarily from cancer-related cachexia, a wasting condition associated with advanced cancer that involves severe muscle loss, restricting calories or carbohydrates could be actively harmful.²⁸ Nobody should adopt a ketogenic or fasting protocol for cancer without medical supervision.

Drugs That Target Glucose Uptake

Researchers are not leaving cancer’s glucose dependence to dietary interventions alone. Pharmaceutical approaches aimed at disrupting how tumors absorb and process glucose are under active investigation. Metformin, a widely used diabetes drug, has attracted attention for its potential anticancer effects. It activates a cellular energy sensor called AMPK, which can disrupt growth signals, slow cell division, and push cancer cells toward energy crisis. Metformin also lowers circulating insulin and IGF-1 levels, which may independently slow tumor progression.²⁹ In lab studies, metformin interfered with cancer cell energy production and triggered cell death through multiple mechanisms.³⁰

Another class of diabetes medications, SGLT2 inhibitors, blocks a specific glucose transporter that some cancers overexpress. Because SGLT2 is not the main glucose transporter used by most healthy cells, blocking it could theoretically cut glucose supply to tumors without causing widespread harm, an advantage over trying to block the more universally important GLUT transporters.³¹ Preclinical studies have shown anticancer effects of SGLT2 inhibitors in breast, liver, pancreatic, and lung cancer models, among others.³² These drugs remain experimental for cancer treatment, but they illustrate how seriously researchers are taking the glucose-cancer connection while recognizing that dietary restriction alone is too blunt an instrument.

Glucose Competition With the Immune System

There is one more twist that complicates the picture. Your immune system’s frontline cancer-fighting cells, particularly certain T cells and other immune responders, also need glucose to do their job. Tumors and immune cells essentially compete for the same fuel in the area around the tumor. Cancer cells, with their souped-up glucose transporters and glycolytic enzymes, tend to win this competition, creating a glucose-poor environment that weakens immune function right where it is needed most.³³ In a mouse study, tumors that consumed more glucose left T cells metabolically hobbled, with reduced ability to produce the signaling molecules needed to attack the tumor.³⁴

This creates a paradox for anyone thinking about cutting carbs to fight cancer. If restricting dietary carbohydrate could somehow reduce glucose availability in the tumor’s neighborhood, it might also further starve the very immune cells trying to destroy the tumor. The immune system is not an outside spectator in cancer. It is an active combatant, and it runs partly on the same fuel that tumors use. Any strategy that lowers glucose in the tumor environment has to contend with the possibility of collateral damage to the immune response. This is one of the reasons why pharmacological approaches that selectively target tumor glucose uptake, leaving immune cells relatively untouched, are so attractive in principle.

What This Means for Your Plate

If you or someone you know has cancer, or you are simply trying to reduce your risk, the practical guidance that falls out of this research is less dramatic than “stop eating carbs” but more actionable. Prioritize carbohydrates that are digested slowly: vegetables, legumes, whole grains, and whole fruits. These keep blood sugar relatively stable and deliver fiber that feeds beneficial gut bacteria. Limit sugar-sweetened drinks, refined sugars, and foods that cause sharp blood sugar spikes. Maintain a healthy weight and stay physically active, because the metabolic conditions most clearly linked to cancer, including insulin resistance, chronic hyperglycemia, and metabolic syndrome, are driven largely by those broader lifestyle factors rather than by carbohydrate intake alone.

Avoid eliminating entire food groups without medical guidance, especially during cancer treatment when the body’s caloric and nutritional needs are heightened. The evidence for ketogenic or fasting-mimicking diets as cancer therapies is still emerging and applies specifically to supervised, add-on protocols alongside conventional treatment. Blanket carbohydrate restriction has no strong evidence supporting it as a cancer prevention strategy, and it can cause malnutrition in people who are already metabolically stressed by disease.